Generated by AI
Sanofi ADR is an American Depositary Receipt representing shares of Sanofi, a global healthcare company focused on pharmaceuticals and vaccines. Through its ADR program, U.S. investors can access the company’s ordinary shares in a form that is traded in the United States, while the underlying business remains centered in France. Sanofi develops, manufactures, and commercializes prescription medicines across several therapeutic areas, including specialty care, general medicines, and immunology, and it also operates a major vaccines business. The company serves patients, healthcare providers, and public health systems in markets around the world, with products used in chronic, rare, and infectious diseases. Sanofi ADR reflects the company’s broad role in the global biopharmaceutical market, combining research, production, and distribution capabilities with a diversified healthcare portfolio.
Website46, avenue de la Grande ArmEe
Paris, 75017
France
The latest articles about SNY.
Sanofi today announced the successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), marked by a signed Letter of Intent (LOI) for Sarclisa® (isatuximab) intravenous (IV) in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the first-line treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant (ASCT).
Summary of Nov 4's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
Investors talking about SNY also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.